Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Kalaris Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Kalaris Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Vandekop Amy O'Leary | VP, Corporate Controller | – | Aug 28, 2026 | 1 |
| Keating Laurie | Director | – | Aug 3, 2026 | 1 |
| Bayko Liisa Ann | Chief Financial Officer | – | Jul 20, 2026 | 1 |
| Patterson Leone D | Director | – | Jun 4, 2026 | 1 |
| Akkaraju Srinivas | Director | 19,408Indirect | Jun 4, 2026 | 4 |
| Adamis Anthony P | Director | – | Jun 4, 2026 | 1 |
| Hallal David | Director | 2,143,662 | Jun 4, 2026 | 1 |
| Jovan-Embiricos Morana | Director | 100,197 | Jun 4, 2026 | 1 |
| Dybbs Michael | Director | – | Jun 4, 2026 | 1 |
| Ferrara Napoleone | Director | 504,000 | Jun 4, 2026 | 1 |
| Samsara BioCapital, L.P. | 10% Owner | 19,408Indirect | May 22, 2026 | 2 |
| Samsara BioCapital GP, LLC | 10% Owner | 19,408Indirect | May 22, 2026 | 2 |
| Samsara Opportunity Fund, L.P. | 10% Owner | 19,408Indirect | May 22, 2026 | 3 |
| Samsara Opportunity Fund GP, LLC | 10% Owner | 19,408Indirect | May 22, 2026 | 3 |
| Hagen Brett R | Chief Accounting Officer | 0 | Mar 23, 2026 | 1 |
| Feinsod Matthew | Chief Medical Officer | 4,030 | Mar 20, 2026 | 1 |
| Oxtoby Andrew | See Remarks | – | Mar 20, 2026 | 1 |
| Gall Matthew | Chief Financial Officer | – | Mar 20, 2026 | 2 |
| Patel Samir Chandrakant | Director | 100,800Indirect | Apr 11, 2025 | 0 |
| Sinha Vikas | See Remarks | 49,129 | Feb 24, 2025 | 0 |
| Miller Edward | General Counsel | 6,517 | Feb 24, 2025 | 0 |
| Brainard Diana | Chief Executive Officer | 723,363 | Nov 20, 2024 | 0 |
| Bornstein Jeffrey S | Director | 110,197 | Jun 7, 2024 | 0 |
| Tomasello Shawn | Director | 70,000 | Jun 7, 2024 | 0 |
| Vera Juan | Director | 2,409,928 | Jun 7, 2024 | 0 |
| Brenner Malcolm | Director | 100,197 | Jun 7, 2024 | 0 |
| Adams Derek N. | Director | 70,000 | Jun 7, 2024 | 0 |
| Piccina Cintia | Chief Commercial Officer | 147,000 | Jul 5, 2023 | 0 |
| Gilead Sciences, Inc. | 10% Owner | 16,635,286 | Jun 28, 2023 | 0 |
| Leen Ann M. | Chief Scientific Officer | 124,006 | Feb 3, 2023 | 0 |
| Van Beek Jeroen B | Chief Commercial Officer | 333,726 | Nov 18, 2022 | 0 |
| Atillasoy Ercem | See Remarks | 131,372 | Oct 26, 2022 | 0 |
| Gadicke Ansbert | Director, 10% Owner | 16,674,766Indirect | Aug 1, 2022 | 0 |
| ElevateBio, LLC | Director, 10% Owner | 16,674,766 | Aug 1, 2022 | 0 |
| Melian Agustin | Chief Medical Officer | 453,529 | Oct 5, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 3, 2021 (view filing) | Dec 2 | 1 day | Van Beek Jeroen BChief Commercial Officer | SSale | −514 | $17.06 | −$8.77K | −0.1%402.9K after | |
| Nov 18, 2021 (view filing) | Nov 16 | 2 days | Van Beek Jeroen BChief Commercial Officer | SSale | −15.2K | $21.13 | −$321.2K | −3.6%403.4K after | |
| Nov 16, 2021 (view filing) | Nov 12-16 | 4 days | Leen Ann M.Chief Scientific Officer | SSale | −21.0K | $22.18 | −$465.5K | −0.9%2.29M after | 4 lots |
| Nov 15, 2021 (view filing) | Nov 10 | 5 days | Jovan-Embiricos MoranaDirector | SSale | −800 | $24.77 | −$19.8K | −0.2%342.7K after | 2 lots |
| Nov 9, 2021 (view filing) | Nov 5-9 | 4 days | Jovan-Embiricos MoranaDirector | SSale | −12.2K | $24.80 | −$302.4K | −3.4%342.8K after | 4 lots |
| Oct 29, 2021 (view filing) | Oct 27 | 2 days | Jovan-Embiricos MoranaDirector | SSale | −2.20K | $24.78 | −$54.5K | −0.6%344.6K after | 2 lots |
| Oct 25, 2021 (view filing) | Oct 21-25 | 4 days | Jovan-Embiricos MoranaDirector | SSale | −13.6K | $24.80 | −$337.1K | −3.8%345.0K after | 6 lots |
| Oct 25, 2021 (view filing) | Oct 21 | 4 days | Atillasoy ErcemSee Remarks | SSale | −1.51K | $24.23 | −$36.7K | −1.4%105.0K after | |
| Oct 5, 2021 (view filing) | Oct 4 | 1 day | Melian AgustinChief Medical Officer | SSale | −18.7K | $23.91 | −$446.9K | −4.0%453.5K after | 4 lots |
| Oct 1, 2021 (view filing) | Sep 29-Oct 1 | 2 days | Van Beek Jeroen BChief Commercial Officer | SSale | −16.6K | $25.14 | −$416.9K | −3.8%418.6K after | 3 lots |
| Sep 29, 2021 (view filing) | Sep 28 | 1 day | Melian AgustinChief Medical Officer | SSale | −3.75K | $24.12 | −$90.5K | −0.8%472.2K after | |
| Sep 20, 2021 (view filing) | Feb 17-Sep 17 | 215 daysLate | Van Beek Jeroen BChief Commercial Officer | SSale | −53.1K | $26.57 | −$1.41M | −10.9%435.2K after | 7 lots |
| Sep 20, 2021 (view filing) | Apr 5-Sep 17 | 168 daysLate | Melian AgustinChief Medical Officer | SSale | −40.5K | $22.11 | −$896.7K | −7.9%476.0K after | 4 lots |